We collaborate with global pharmaceutical companies, investors, and academic centers to accelerate early development. EDE offers flexible business models to accelerate innovation, reduce cost, and strengthen your R&D pipeline.
With full preclinical data, proof-of-concept in vitro results, and API/material transfer for validation purposes.
- Free API supply for internal validation leading to faster pipeline progression
- In-vitro & in-vivo testing without API cost to reduce upfront cost
- Early engagement with regulatory authorities to reduce risk and improve commercial alignment.
Know-how for any compound to be manufactured at the pharmaceutical’s site
- Full manufacturing documentation (purity, stability, methods) leading to secure supply and internal control
- 30% cost savings compared to market synthesis leading to reduced manufacturing cost
- No reliance on third-party API suppliers
- Shorter scale-up timeline
For target identification, MoA analysis, and compound discovery
- High-speed, science-driven discovery engine leading to shortened discovery cycles, higher hit quality and increased clinical success probability
- Proprietary scientific genomic modeling platform enabling reduced R&D cost
- Customizable programs for your pipeline
Pharma shares therapeutic area or specific target of interest.
EDE recommends relevant, in vitro-validated assets from our 1,000+ library across multiple therapeutic areas.
EDE and Pharma review internal data and discuss the asset's development potential.
If the asset meets Pharma's criteria, we move to licensing or co-development agreement.
For global collaborations, licensing discussions, scientific partnerships, and investor relations
